Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2017

On Aug. 2, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against recommending approval of sirukumab for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults who have had an inadequate response to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).1 The committee cited safety concerns and voted 12–1 that the benefits of the treatment do not outweigh its risks.2

According to the innovator company, Johnson & Johnson, sirukumab is an anti-interleukin (IL)-6 monoclonal antibody, but it blocks the IL-6 pathway differently from other IL-6 inhibitors that are currently FDA approved for treating RA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At the advisory committee meeting, the efficacy and safety data of sirukumab was reviewed. This data came from five Phase 3 clinical trials with more than 3,000 patients with RA, who include patients with active disease despite previous DMARD and biologic treatment. Doses used in the trials included 50 mg sirukumab every four weeks and 100 mg sirukumab every two weeks. The agent showed significant efficacy in improving the signs and symptoms of RA, inhibiting structural damage progression and showing improvements in measured patient-reported outcomes, such as fatigue, pain, physical function and quality of life.

During the trials, common adverse events included laboratory abnormalities, colds, upper respiratory tract infections and injection site redness, pain or swelling. Serious adverse events included infections, such as abscess, cellulitis, gastrointestinal perforations, hypersensitivity reactions, lipid level elevations, osteomyelitis, pneumonia, thrombocytopenia and sepsis. Cardiovascular adverse events, malignancies and deaths were also observed.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Johnson & Johnson Services Inc. News release: FDA advisory committee does not recommend approval of sirukumab for the treatment of moderately to severely active rheumatoid arthritis. 2017 Aug 2.
  2. Barber J. FDA advisory panel votes against approval of Johnson & Johnson’s experimental RA drug, Plivensia. FirstWord Phrama. 2017 Aug 2.

Share: 

Filed under:Biologics/DMARDsDrug Updates Tagged with:Drug SafetyFDAFood and Drug AdministrationRheumatoid Arthritis (RA)sirukumab

Related Articles

    Sirukumab Promising for RA

    April 4, 2017

    In a clinical trial, RA patients on sirukumab experienced decreased disease activity and improved physical function…

    Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis

    May 16, 2017

    Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…

    Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

    September 17, 2017

    Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

    3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

    January 27, 2016

    Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences